BCRX: Cup Handle detected on 17 Mar 2026

On March 16, 2026, BCRX surged 11.3% into a classic cup-handle formation at $9.30. The pattern exhibits strong structure scoring 13.75 and solid breakout momentum at 11.7, indicating constructive accumulation. Volume is elevated at 3.48x average (19.8M shares), providing credible support. Key support sits at $8.15 and resistance at $8.75. The pattern has built over multiple waves—a post-collapse recovery spanning 104 days, a bull flag formed on Feb 5, and a bullish engulfing on Mar 13. The overall score of 86.25 with 80.36% win probability signals a high-quality setup approaching a breakout attempt.

BioCryst reported Q4 2025 earnings per share of $1.12 with revenue of $406.6M, marking a dramatic turnaround from prior losses. ORLADEYO net revenue reached $601 million for full year 2025, up 37% year-over-year, with U.S. revenue at $563 million (+43%). BioCryst completed the Astria Therapeutics acquisition on January 23, 2026, adding navenibart, a Phase 3 long-acting plasma kallikrein inhibitor, dramatically expanding its hereditary angioedema franchise. Evercore ISI reinstated coverage with an Outperform rating and $17 price target, while Wedbush raised its target to $22. FDA approved ORLADEYO oral pellets in December 2025 for ages 2-12, making it the first oral prophylactic therapy for HAE patients aged 2 and older. The pattern is forming NOW because real profitability has arrived—earnings surprise, revenue acceleration, and strategic expansion coincide with analyst enthusiasm.

A cup-handle breakout above $8.75 resistance with volume confirmation would target $10.11 conservatively. Historical breakout success at 80% probability suggests a measured move of ~$1.25 above the breakout point. Volume should sustain above 3x average (5.7M shares/day baseline) to validate the move. Invalidation triggers below $8.15 support, where the pattern structure fails. The Bollinger Band position of 0.952 indicates price is near the upper band, suggesting limited room for consolidation—a breakout move is imminent. The RSI at 72.04 shows overbought conditions, which in strong uptrend contexts often precedes further advances rather than pullbacks.

Insider activity shows two insider selling transactions over the past three months with no insider buying, which may warrant scrutiny. The company's debt-to-equity ratio of -3.68 indicates negative equity position, and an Altman Z-Score of 2.26 places the firm in the grey area of financial stress. Projected three-year CAGR for operating income is -10% and net income is -21%, signaling earnings may decline despite current profitability. The healthcare sector is trading bearish (regime score -0.17), creating headwinds. Volatility at 53.84% is elevated and beta is low at 0.63; however, at RSI 72.04, overbought extremes can unwind quickly on profit-taking. The Astria acquisition adds integration execution risk and dilution—equity issuance of 37.3M shares was material. Monitor analyst revisions closely in coming weeks.